Dr Reddy's & FDC Recall Products in US for Manufacturing Issues

By By Rediff Money Desk, New Delhi
Nov 17, 2024 11:25
Dr Reddy's Laboratories and FDC Ltd are recalling generic medications in the US due to manufacturing issues. The recall affects Morphine Sulfate extended-release tablets and Timolol Maleate ophthalmic solution.
New Delhi, Nov 17 (PTI) Dr Reddy's Laboratories and FDC Ltd are recalling generic medications in the US market due to manufacturing issues, according to the US health regulator.

As per the latest Enforcement Report by Food and Drug Administration (USFDA), the US-based subsidiary of Dr Reddy's Laboratories is recalling multiple strengths of Morphine Sulfate extended-release tablets in the US.

The medication is used to relieve severe and persistent pain.

As per the USFDA, Princeton-based Dr Reddy's Laboratories Inc is recalling 2,040 bottles of 15 mg Morphine Sulfate extended-release tablets due to "Failed Impurities/Degradation Specification".

The drugmaker is also recalling another 532 100-count bottles of the medication in 30 mg strength for the same reason, USFDA stated.

Dr Reddy's initiated the Class II nationwide recall on October 22 this year.

USFDA said Mumbai-headquartred FDC Ltd is recalling 1,55,232 bottles of Timolol Maleate ophthalmic solution in the US market.

The company is recalling the affected lot due to "Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle", the US health regulator stated.

The company initiated the Class II recall on October 29, 2024.

Timolol Maleate ophthalmic solution is used to treat high pressure inside the eye due to glaucoma.

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

India is the largest supplier of generic medicines with around 20 per cent share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.

The products manufactured in the country are shipped to over 200 countries around the globe, with Japan, Australia, West Europe, and the US as the main destinations.
Source: PTI
Read More On:
dr reddy'sfdcgeneric medicationsusfdarecallmanufacturing issuesmorphine sulfatetimolol maleateophthalmic solutiondrug recallpharmaceutical industryindiageneric drugsglobal supply
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Unilever: India Growth & GST Impact

Unilever sees huge opportunities in India due to high GDP growth and GST cuts. HUL...

Trai Recommends 6 GHz, E, V Band Allocation

Trai suggests administrative allocation of 6 GHz, E, and V bands for telecom backhaul....

TotalEnergies Sells Stake in Adani Green Energy

TotalEnergies sells 1.74% stake in Adani Green Energy for Rs 2,778 cr. Stake reduced to...

TCS Acquires Coastal Cloud for $700 Million

TCS acquires Coastal Cloud for USD 700 million, strengthening its Salesforce and AI...

JSW Paints Acquires AkzoNobel India Stake

JSW Paints completes acquisition of majority stake in AkzoNobel India, becoming the...

Park Medi World IPO Subscribed 52% on Day 1

Park Medi World''s IPO received 52% subscription on day 1. The Rs 920-crore IPO closes...

Dasnac Invests Rs 2,000 Cr in Noida Luxury Housing

Dasnac to invest Rs 2,000 crore in a luxury housing project, Dasnac Westminster, in...

Nephrocare IPO Subscribed 12% on Day 1

Nephrocare Health Services IPO received 12% subscription on day 1. IPO details, price...

Wakefit IPO Subscribed Over 2 Times

Wakefit''s Rs 1,289-cr IPO was subscribed over 2 times on the final day. Details on...

IAN Group to Deploy USD 100M Alpha Fund by 2027

IAN Group to deploy its USD 100 million IAN Alpha Fund in early-stage startups by 2027....

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com